Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant metastatic colorectal carcinoma (mCRC) patients treated with RG7160 (GA201), an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal anti-EGFR antibody.
Jean-Pierre Delord
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Rocio Garcia-Carbonero
Consultant or Advisory Role - Amgen (B); Bayer (B,U); Merck (B); Roche (B)
Honoraria - Amgen (B); Bayer (B); Merck (B); Roche (B)
Andres Cervantes-Ruiperez
Consultant or Advisory Role - Roche
Honoraria - Roche
Carlos Alberto Gomez-Roca
No relevant relationships to disclose
Yann Berge
No relevant relationships to disclose
Jaume Capdevila
No relevant relationships to disclose
Jesus Corral Jaime
No relevant relationships to disclose
Desamparados Roda Perez
No relevant relationships to disclose
Sophie Golding
Employment or Leadership Position - Roche
Stock Ownership - Roche
David Oppenheim
Research Funding - Roche
Other Remuneration - Roche
Sophia Soehrman Brossard
Employment or Leadership Position - Roche
Christoph Mancao
Employment or Leadership Position - Roche
Stock Ownership - Roche
Farzin Farzaneh
Research Funding - Roche
Other Remuneration - Roche
Alexandre Passioukov
Employment or Leadership Position - Roche
Luigi Manenti
Employment or Leadership Position - Roche
Stock Ownership - Roche
Marion Gabriele Ott
Employment or Leadership Position - Roche
Jean-Charles Soria
Honoraria - Roche